BRCA1 and BRCA2: Chemosensitivity, treatment outcomes and prognosis

Familial Cancer

Volumn 5, Issue 2, 2006, Pages 135-142

  Foulkes, William D ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Chemotherapy; Hereditary breast and ovarian cancer; Oncology; Survival

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; BUSULFAN; CAMPTOTHECIN; CISPLATIN; CLENBUTEROL; CYCLIN E; CYTOKERATIN 5; CYTOKERATIN 6; DOCETAXEL; DOUBLE STRANDED DNA; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PLATINUM DERIVATIVE; RAD51 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME BREAKAGE; CLINICAL FEATURE; DNA MICROARRAY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG SENSITIVITY; FANCONI ANEMIA; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33744760541     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-005-2832-5     Document Type: Article

References (85)

1. SA Narod WD Foulkes 2004 BRCA1 and BRCA2: 1994 and beyond Nat Rev Cancer 4 9 665 76
2. A Andermann SA Narod 2002 Genetic counselling for familial breast and ovarian cancer in Ontario J Med Genet 39 9 695 6
3. DG Evans A Howell 2004 Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? Breast Cancer Res 6 1 E7
4. T Sorlie CM Perou R Tibshirani 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 74
5. LJ Van't Veer HY Dai MJ van de Vijver 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 530 6
6. C Sotiriou SY Neo LM [tmp] McShane 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 18 10393 8
7. I Hedenfalk D Duggan Y Chen 2001 Gene-expression profiles in hereditary breast cancer N Engl J Med 344 8 539 48
8. C Sotiriou C Khanna AA Jazaeri 2002 Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays J Mol Diagn 4 1 30 6
9. SR Lakhani MJ van de Vijver J Jacquemier 2002 The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 9 2310 8
10. WD Foulkes K Metcalfe W Hanna 2003 Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma Cancer 98 8 1569 77
11. PO Chappuis V Nethercot WD Foulkes 2000 Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer Semin Surg Oncol 18 287 95
12. PO Chappuis L Kapusta LR Begin 2000 Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer J Clin Oncol 18 24 4045 52
13. MS Greenblatt PO Chappuis JP Bond 2001 TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution Cancer Res 61 10 4092 7
14. WD Foulkes JS Brunet IM Stefansson 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 3 830 5
15. T Sorlie R Tibshirani J Parker 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 14 8418 23
16. WD Foulkes IM Stefansson PO Chappuis 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 1482 5
17. JR Goffin O Straume PO Chappuis 2003 Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer Br J Cancer 89 6 1031 4
18. TA Grushko JJ Dignam S Das 2004 MYC is amplified in BRCA1-associated breast cancers Clin Cancer Res 10 2 499 507
19. C Adem CL Soderberg K Hafner 2004 ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers Genes Chromosomes Cancer 41 1 1 11
20. E Korsching J Packeisen K Agelopoulos 2002 Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis Lab Invest 82 11 1525 33
21. S Signoretti L Di Marcotullio A Richardson 2002 Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer J Clin Invest 110 5 633 41
22. K Malzahn M Mitze M Thoenes R Moll 1998 Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas Virchows Arch Int J Pathol 433 2 119 29
23. SH Dairkee BH Mayall HS Smith AJ Hackett 1987 Monoclonal marker that predicts early recurrence of breast-cancer Lancet 1 8531 514
24. M van de Rijn CM Perou R Tibshirani 2002 Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 161 6 1991 6
25. SR Lakhani J Jacquemier JP Sloane 1998 Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations J Natl Cancer Inst 90 15 1138 45
26. SA Vaziri RR Tubbs G Darlington G Casey 2001 Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers Mol Pathol 54 4 259 63
27. R Desper J Khan AA Schaffer 2004 Tumor classification using phylogenetic methods on expression data J Theor Biol 228 4 477 96
28. A Fedier RA Steiner VA Schwarz 2003 The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells Int J Oncol 22 5 1169 73
29. JE Quinn RD Kennedy PB Mullan 2003 BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 63 19 6221 8
30. M Thangaraju SH Kaufmann FJ Couch 2000 BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines J Biol Chem 275 43 33487 96
31. C Zhou JL Smith J Liu 2003 Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 Oncogene 22 16 2396 404
32. P Tassone P Tagliaferri A Perricelli 2003 BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells Br J Cancer 88 8 1285 91
33. Samouelian V, Maugard CM, Jolicoeur M et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004
34. A Husain G He ES Venkatraman DR Spriggs 1998 BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II) Cancer Res 58 6 1120 3
35. A Bhattacharyya US Ear BH Koller 2000 The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross- linking agent cisplatin J Biol Chem 275 31 23899 903
36. DW Abbott ML Freeman JT Holt 1998 Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells J Natl Cancer Inst 90 13 978 85
37. ME Moynahan TY Cui M Jasin 2001 Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation Cancer Res 61 12 4842 50
38. KJ Patel VP Yu H Lee 1998 Involvement of Brca2 in DNA repair Mol Cell 1 3 347 57
39. R Scully DM Livingston 2000 In search of the tumour-suppressor functions of BRCA1 and BRCA2 Nature 408 6811 429 32
40. X Xu W Qiao SP Linke 2001 Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis Nat Genet 28 3 266 71
41. D Cortez Y Wang J Qin SJ Elledge 1999 Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks Science 286 5442 1162 6
42. KK Khanna SP Jackson 2001 DNA double-strand breaks: Signaling, repair and the cancer connection Nat Genet 27 3 247 54
43. SSF Yuan SY Lee G Chen 1999 BRCA2 is required for ionizing radiation-induced assembly of rad51 complex in vivo Cancer Res 59 15 3547 51
44. P Freneaux D Stoppa-Lyonnet E Mouret 2000 Low expression of bcl-2 in Brca1-associated breast cancers Br J Cancer 83 10 1318 22
45. PC Hanawalt 2001 Revisiting the rodent repairadox Environ Mol Mutagen 38 2-3 89 96
46. C Egawa K Motomura Y Miyoshi 2003 Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers Breast Cancer Res Treat 78 1 45 50
47. A Catteau WH Harris CF Xu E Solomon 1999 Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics Oncogene 18 11 1957 65
48. M Esteller JM Silva G Dominguez 2000 Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 7 564 9 (see comments)
49. M Esteller J Garcia-Foncillas E Andion 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 19 1350 4
50. S Geisler PE Lonning T Aas 2001 Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer Cancer Res 61 6 2505 12
51. S Geisler AL Borresen-Dale H Johnsen 2003 TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer Clin Cancer Res 9 15 5582 8
52. W Henning HW Sturzbecher 2003 Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance Toxicology 193 1-2 91 109
53. E Levy-Lahad A Lahad S Eisenberg 2001 A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers Proc Natl Acad Sci USA 98 6 3232 6
54. WW Wang AB Spurdle P Kolachana 2001 A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers Cancer Epidemiol Biomarkers Prev 10 9 955 60
55. L Kadouri Z Kote-Jarai A Hubert 2004 A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers Br J Cancer 90 10 2002 5
56. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14; 434(9035): 913-7
57. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 14; 434(7035): 917-21
58. PO Chappuis J Goffin N Wong 2002 A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer J Med Genet 39 8 608 10
59. E Warner M Trudeau C Holloway 2003 Sensitivity of BRCA-1- related breast cancer to neoadjuvant chemotherapy: Practical implications Breast J 9 6 507 8
60. ME Robson PO Chappuis J Satagopan 2004 A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 6 1 R8 R17
61. J Boyd Y Sonoda MG Federici 2000 Clinicopathologic features of BRCA-linked and sporadic ovarian cancer JAMA 283 17 2260 5
62. SJ Ramus A Fishman PD Pharoah 2001 Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations Eur J Surg Oncol 27 3 278 81
63. Y Ben David A Chetrit G Hirsh-Yechezkel 2002 Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 2 463 6
64. I Cass RL Baldwin T Varkey 2003 Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 9 2187 95
65. AC Wolff NE Davidson 2002 Preoperative therapy in breast cancer: Lessons from the treatment of locally advanced disease Oncologist 7 3 239 45
66. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15; 11(16): 5678-85
67. TA Buchholz 2005 The nuclear transcription factor kappaB/bc1-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer Clin Cancer Res. 11 23 8398 8402
68. JV Moyano 2006 AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer J Clin Invest. 116 1 261 270
69. HY Chang 2005 Robustness, Scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci U.S.A. 102 10 3738 3743
70. SM Rodriguez-Pinilla 2006 Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas Clin Cancer Res. 12 5 1533 1539
71. Banerjee S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J clin Pathol
72. PD Pharoah DF Easton DL Stockton 1999 Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group Cancer Res 59 4 868 71
73. RP Zweemer RH Verheijen JW Coebergh 2001 Survival analysis in familial ovarian cancer, a case control study Eur J Obstet Gynecol Reprod Biol 98 2 219 23
74. A Wojciechowska-Lacka J Markowska E Skasko 2003 Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report) Eur J Gynaecol Oncol 24 1 21 4
75. MD Tischkowitz SV Hodgson 2003 Fanconi anaemia J Med Genet 40 1 1 10
76. NG Howlett T Taniguchi S Olson 2002 Biallelic inactivation of BRCA2 in Fanconi anemia Science 297 5581 606 9
77. AR Venkitaraman 2004 Tracing the network connecting BRCA and Fanconi anaemia proteins Nat Rev Cancer 4 4 266 76
78. T Taniguchi M Tischkowitz N Ameziane 2003 Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 9 5 568 74
79. JL Hilton JP Geisler JA Rathe 2002 Inactivation of BRCA1 and BRCA2 in ovarian cancer J Natl Cancer Inst 94 18 1396 406
80. ME Robson J Boyd PI Borgen HS Cody III 2001 Hereditary breast cancer Curr Probl Surg 38 6 387 480
81. WD Foulkes J Rosenblatt PO Chappuis 2001 The contribution of inherited factors to the clinicopathological features and behavior of breast cancer J Mammary Gland Biol Neoplasia 6 4 453 65
82. Lakhani SR, Gusterson BA, Jacquemier J et al. The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6(3): 782-9
83. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74(6): 1175-82
84. MD Schwartz C Lerman B Brogan 2004 Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients J Clin Oncol 22 10 1823 9
85. B Weigelt Z Hu X He C Livasy LA Carey MG Ewend AM Glas CM Perou LJ Van't Veer 2005 Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer Cancer Res. 65 20 9155 8